Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring-guided adalimumab interval prolongation in rheumatoid arthritis
NL-OMON29559Not yet recruiting
- Sponsor
- Reumafonds Reade, centrum voor revalidatie en reumatologie
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in rheumatoid arthritis (RA) (2 arms), sponsored by Reumafonds Reade, centrum voor revalidatie en reumatologie. Planned start Oct 2012; status: not yet recruiting.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON29559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29559.